View in browser
358 LIME Newsletter v1 600x300
ICT 2022: Spotlight on new opportunities for skin sensitization testing with GARDskin OECD TG 442E
We had an interesting and rewarding time at this year’s ICT live meeting, catching up with all our colleagues in the area of in vitro toxicology. Together with guest speaker Dr Marco Corvaro, Principal Toxicologist from Corteva Agriscience, we presented new data on agrochemical formulations, “difficult-to-test” substances and potency assessment.
962 ICT2022 640x640transp
1008 2022 ICT booth with visitors 640x640transp
1013 20220920 123421
1016 Andy presenting 1 edited
New data on fragrance materials: the use of GARDskin Dose-Response for quantitative potency assessment
Dr Andy Forreryd of SenzaGen presenting new data on quantitative potency assessment of fragrance materials using GARDskin Dose-Response.
1009 Marco presenting
Scientific session with Corteva Agriscience: The use of GARD for agrochemical formulations
Guest speaker Dr Marco Corvaro presenting the applicability domain of GARD®skin and GARD®potency for agrochemical formulations.
Register for the ICT recap webinar on Oct 12
984 80A2034
Chemicals company strengthens weight of evidence assessment of difficult-to-test samples
Recently, one of our customers in the chemicals industry used the GARD®skin assay for their difficult-to-test samples. The aim of the project was to develop additional data to strengthen their weight of evidence assessments, in order to have greater confidence in that their products are classified appropriately with regards to skin sensitization potential. This is further proof that GARDskin works for a wide variety of test chemicals, including UVCBs, surfactants and hydrophobic test items.

Read more about the broad applicability of the GARDskin method
969 80A1976
Regulatory update: How to use in vitro assays in the biological evaluation of Medical Devices
At both live and virtual events this fall, SenzaGen's Medical Device specialist and ISO expert Dr Rose-Marie Jenvert discusses new approaches to in vitro sensitization testing as part of the biological evaluation of medical devices, and the status of regulatory acceptance. Together with experts from VitroScreen, she also shares experiences from in vitro penetration, distribution and absorption studies for classification and safety assessment of substance-based medical devices (MDR, Rule 21).
Register for the Medical Device webinar on Oct 26
Upcoming events
🌎 Conference: Biocompatibility Matters
Oct 5-6 | Copenhagen

🎧 Webinar: Recap on SenzaGen’s 2022 ICT Industry Symposium

Oct 12, CEST 16.00-17.00

🌎 Conference:ASCCT
Oct 19-21 | Chapel Hill, N.C.,USA

🎧 Webinar: How to use in vitro assays in your biological evaluation

Oct 26, CEST 16.00-17.00
945 LInkedIn versaler
Click to visit us on Twitter
Click to visit us on LinkedIn
Click to visit us our homepage
You are receiving this email because you expressed interest in SenzaGen's technology in the past.
Unsubscribe here if you do not wish to receive technology updates and news from us.
open